Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Degenerative Disc Disease - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Degenerative Disc Disease - Pipeline Review, H1 2016', provides an overview of the Degenerative Disc Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Degenerative Disc Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease - The report reviews pipeline therapeutics for Degenerative Disc Disease by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Degenerative Disc Disease therapeutics and enlists all their major and minor projects - The report assesses Degenerative Disc Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Degenerative Disc Disease Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Degenerative Disc Disease - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Degenerative Disc Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Degenerative Disc Disease Overview 8 Therapeutics Development 9 Pipeline Products for Degenerative Disc Disease - Overview 9 Pipeline Products for Degenerative Disc Disease - Comparative Analysis 10 Degenerative Disc Disease - Therapeutics under Development by Companies 11 Degenerative Disc Disease - Therapeutics under Investigation by Universities/Institutes 12 Degenerative Disc Disease - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Degenerative Disc Disease - Products under Development by Companies 17 Degenerative Disc Disease - Products under Investigation by Universities/Institutes 18 Degenerative Disc Disease - Companies Involved in Therapeutics Development 19 AnGes MG, Inc. 19 Biogenomics Limited 20 Biopharm GmbH 21 BioRestorative Therapies, Inc. 22 Bone Therapeutics SA 23 DiscGenics, Inc. 24 ISTO Technologies, Inc. 25 K-Stemcell Co., Ltd. 26 Mesoblast Limited 27 TissueGene, Inc. 28 U.S. Stem Cell, Inc. 29 Yuhan Corporation 30 Degenerative Disc Disease - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 AdipoCell - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 ALLOB - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 AMG-0103 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 BRTX-100 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 CHND-1 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 dibotermin alfa - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 MPC-25Osteo - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 NuQu - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Poly N-Acetyl Glucosamine Hydrogel - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Recombinant Protein for Degenerative Disc Disease, Bone Fracture, Parkinson's Disease and Erectile Dysfunction - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 S-414114 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small Molecules for Degenerative Disc Disease - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Stem Cell Therapy for Degenerative Disc Disease - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Stem Cell Therapy for Degenerative Disc Disease - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology and Cardiovascular Disease - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 TG-D - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 YH-14618 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Degenerative Disc Disease - Recent Pipeline Updates 66 Degenerative Disc Disease - Dormant Projects 72 Degenerative Disc Disease - Product Development Milestones 73 Featured News & Press Releases 73 Feb 09, 2016: BioRestorative Therapies Names Lead Cell-Based Lumbar Disc Therapeutic Product 73 Jul 27, 2015: Denver Back Pain Specialists Physicians Begin Enrollment in Stem Cell Therapy Study in Subjects with Chronic Back Pain 73 Jan 12, 2015: BioRestorative Therapies Reports Successful Meeting with FDA 74 Nov 24, 2014: BioRestorative Therapies Schedules Pre-IND Meeting With FDA 74 Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease 75 Oct 09, 2014: BioRestorative Therapies Engages Access BIO to Support Advancement of brtxDISC Program into Clinical Studies 75 Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion 76 Mar 26, 2014: Bioheart Announces Clinical Study for Degenerative Disc Disease 76 Jan 29, 2014: Positive Spinal Disc Repair Trial Results Using Mesoblast Adult Stem Cells 77 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 Primary Research 79 Expert Panel Validation 79 Contact Us 79 Disclaimer 80
List of Tables
Number of Products under Development for Degenerative Disc Disease, H1 2016 9 Number of Products under Development for Degenerative Disc Disease - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Comparative Analysis by Unknown Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Degenerative Disc Disease - Pipeline by AnGes MG, Inc., H1 2016 19 Degenerative Disc Disease - Pipeline by Biogenomics Limited, H1 2016 20 Degenerative Disc Disease - Pipeline by Biopharm GmbH, H1 2016 21 Degenerative Disc Disease - Pipeline by BioRestorative Therapies, Inc., H1 2016 22 Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H1 2016 23 Degenerative Disc Disease - Pipeline by DiscGenics, Inc., H1 2016 24 Degenerative Disc Disease - Pipeline by ISTO Technologies, Inc., H1 2016 25 Degenerative Disc Disease - Pipeline by K-Stemcell Co., Ltd., H1 2016 26 Degenerative Disc Disease - Pipeline by Mesoblast Limited, H1 2016 27 Degenerative Disc Disease - Pipeline by TissueGene, Inc., H1 2016 28 Degenerative Disc Disease - Pipeline by U.S. Stem Cell, Inc., H1 2016 29 Degenerative Disc Disease - Pipeline by Yuhan Corporation, H1 2016 30 Assessment by Monotherapy Products, H1 2016 31 Number of Products by Stage and Target, H1 2016 33 Number of Products by Stage and Mechanism of Action, H1 2016 35 Number of Products by Stage and Route of Administration, H1 2016 37 Number of Products by Stage and Molecule Type, H1 2016 39 Degenerative Disc Disease Therapeutics - Recent Pipeline Updates, H1 2016 66 Degenerative Disc Disease - Dormant Projects, H1 2016 72
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.